Alkermes (ALKS) Competitors $26.53 -0.66 (-2.43%) Closing price 04:00 PM EasternExtended Trading$26.95 +0.42 (+1.58%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. ABEO, MEDP, OMCL, AMN, BIIB, INCY, UTHR, NBIX, EXEL, and BMRNShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Alkermes vs. Its Competitors Abeona Therapeutics Medpace Omnicell AMN Healthcare Services Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Do institutionals & insiders have more ownership in ABEO or ALKS? 80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 6.9% of Abeona Therapeutics shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to ABEO or ALKS? In the previous week, Alkermes had 13 more articles in the media than Abeona Therapeutics. MarketBeat recorded 16 mentions for Alkermes and 3 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 0.47 beat Abeona Therapeutics' score of -0.55 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Alkermes 3 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, ABEO or ALKS? Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M97.20-$63.73M-$1.27-5.24Alkermes$1.56B2.81$367.07M$2.0912.69 Do analysts rate ABEO or ALKS? Abeona Therapeutics presently has a consensus price target of $19.25, suggesting a potential upside of 189.47%. Alkermes has a consensus price target of $40.92, suggesting a potential upside of 54.23%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Is ABEO or ALKS more profitable? Alkermes has a net margin of 23.30% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 27.52% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A -118.82% -52.48% Alkermes 23.30%27.52%17.98% Which has more risk & volatility, ABEO or ALKS? Abeona Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. SummaryAlkermes beats Abeona Therapeutics on 12 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.48B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio12.6920.7327.9019.95Price / Sales2.81321.07442.18102.66Price / Cash10.2643.2336.5558.97Price / Book2.938.308.635.90Net Income$367.07M-$55.19M$3.24B$258.42M7 Day Performance-9.64%5.07%3.22%1.94%1 Month Performance-9.61%17.61%10.72%12.02%1 Year Performance0.08%7.03%34.94%20.81% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.7768 of 5 stars$26.53-2.4%$40.92+54.2%+8.8%$4.48B$1.56B12.691,800Upcoming EarningsAnalyst ForecastABEOAbeona Therapeutics3.6772 of 5 stars$5.92+3.1%$19.25+225.2%+30.8%$302.87M$3.50M-4.6690MEDPMedpace3.9576 of 5 stars$320.36-1.0%$344.82+7.6%+22.4%$9.21B$2.11B24.455,900Trending NewsEarnings ReportAnalyst ForecastOMCLOmnicell3.7603 of 5 stars$27.57-3.9%$44.83+62.6%-4.2%$1.29B$1.14B59.943,670Positive NewsUpcoming EarningsAnalyst ForecastAMNAMN Healthcare Services4.3022 of 5 stars$20.72-2.1%$32.08+54.8%-65.8%$793.27M$2.85B-4.792,968BIIBBiogen4.9303 of 5 stars$133.11-0.8%$188.48+41.6%-41.6%$19.50B$9.68B13.147,605Upcoming EarningsAnalyst UpgradeINCYIncyte4.5897 of 5 stars$69.98+2.0%$74.47+6.4%+7.4%$13.55B$4.24B218.692,617Upcoming EarningsInsider TradeUTHRUnited Therapeutics4.9901 of 5 stars$297.68+0.7%$383.08+28.7%-9.2%$13.43B$2.88B11.881,305Positive NewsUpcoming EarningsAnalyst RevisionNBIXNeurocrine Biosciences4.4634 of 5 stars$135.13+1.3%$163.91+21.3%-8.1%$13.37B$2.41B45.811,800Upcoming EarningsAnalyst ForecastEXELExelixis4.8166 of 5 stars$45.58+1.6%$45.22-0.8%+102.1%$12.43B$2.17B20.721,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9779 of 5 stars$58.23+0.2%$93.78+61.1%-29.3%$11.17B$2.85B21.653,040Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Abeona Therapeutics Alternatives Medpace Alternatives Omnicell Alternatives AMN Healthcare Services Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALKS Stock Alerts